TXG
Healthcare10x Genomics, Inc. · Medical - Healthcare Information Services · $3B
What is 10x Genomics, Inc.?
10x Genomics is a life science technology company that builds instruments, consumables, and software enabling researchers to analyze biological systems at the single-cell level. Headquartered in Pleasanton, California, the company serves academic, government, and biopharma institutions worldwide.
The company generates revenue by selling hardware instruments, microfluidic chips, reagents, and software subscriptions to research institutions. Its Chromium platform lets scientists measure gene activity cell by cell, while its Visium platform maps gene expression across tissue samples spatially. Customers span universities, government labs, and biopharmaceutical companies across North America, Europe, the Middle East, Africa, China, and the Asia Pacific.
10x Genomics was incorporated in 2012 and is headquartered in Pleasanton, California.
- Chromium instruments for single-cell gene expression analysis
- Single cell immune profiling and epigenetics (ATAC) solutions
- Single cell multiome ATAC and gene expression combined measurement
- Visium spatial gene expression and protein co-detection platform
- Proprietary microfluidic chips, reagents, and analysis software
Is TXG a Good Stock to Buy?
UQS Score rates TXG as Below Average overall.
The Valuation pillar stands out as a relative bright spot, suggesting the market may already be pricing in much of the company's near-term uncertainty. The Risk pillar also registers as Neutral, meaning the balance sheet and operational risk profile are not at extreme levels relative to sector peers.
Both the Quality and Growth pillars score Weak, reflecting ongoing profitability challenges and limited near-term revenue momentum — common headwinds for early-stage life science tools companies.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does TXG pay dividends?
No — 10x Genomics, Inc. does not currently pay a dividend.
10x Genomics does not currently pay a dividend. This is typical for growth-oriented life science tools companies that reinvest available capital into research, product development, and commercial expansion rather than returning cash to shareholders. Income-focused investors should be aware that no dividend income is available from TXG at this time.
When does TXG report earnings?
10x Genomics reports earnings on a quarterly cadence, consistent with standard practice for US-listed equities.
The company's recent results have reflected the pressures visible in its Weak Quality and Growth pillar ratings — revenue growth has been challenged and profitability remains a work in progress. Instrument placements and consumables pull-through remain key metrics for investors to watch each quarter.
For the most recent quarter's results and guidance, visit 10x Genomics' investor relations page directly.
TXG Price History
-87.2% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in 10x Genomics, Inc.?
Based on 10x Genomics, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
TXG Long-term Outlook
The UQS Growth pillar for TXG is rated Weak, indicating that near-term expansion is not expected to be a primary driver of returns. However, the Neutral Risk rating suggests the company is not in acute financial distress. The path forward depends heavily on adoption of newer spatial biology products and the ability to convert instrument placements into recurring consumables revenue. Valuation rated Good implies the current price may reflect a degree of pessimism already baked in.
Growth drivers
- Expanding adoption of spatial gene expression technology in biopharma research
- Consumables pull-through as the installed instrument base grows over time
- Potential new product launches extending the single-cell and spatial biology platforms
Key risks
- Continued operating losses and cash consumption given Weak Quality pillar
- Competitive pressure in the life science tools market from larger, better-capitalized peers
- Slower-than-expected research spending by academic and government customers
TXG vs Peers
10x Genomics operates in a broader healthcare technology landscape alongside several other innovative companies.
Hinge Health focuses on digital musculoskeletal care rather than genomics instrumentation, serving a distinct patient-facing market.
Privia Health operates a physician enablement and value-based care platform, competing in healthcare services rather than life science tools.
Heartflow applies computational modeling to cardiovascular diagnostics, occupying a different niche within healthcare technology.
Frequently Asked Questions
What does 10x Genomics do?
10x Genomics develops instruments, consumables, and software that allow scientists to analyze biological systems at single-cell resolution. Its Chromium platform measures gene activity and immune cell behavior cell by cell, while its Visium platform maps gene expression spatially across tissue samples. Customers include academic labs, government research institutions, and biopharma companies.
Does TXG pay dividends?
No, 10x Genomics does not currently pay a dividend. The company reinvests available resources into product development and commercial growth, which is typical for life science tools companies at this stage. Investors seeking dividend income should look elsewhere.
When does TXG report earnings?
10x Genomics reports financial results on a quarterly cadence, in line with standard US-listed company practice. For exact dates and the most recent results, check the investor relations section of the 10x Genomics website directly.
Is TXG a good stock to buy?
UQS Score rates TXG as Below Average, driven by Weak Quality and Growth pillar scores. The Valuation pillar is rated Good, which may interest contrarian investors, but the overall profile reflects meaningful fundamental challenges. Reviewing the full pillar breakdown on UQS Pro can help inform a more complete view.
Is TXG overvalued?
The UQS Valuation pillar for TXG is rated Good, suggesting the stock is not considered elevated relative to its fundamentals within the UQS framework. That said, Valuation alone does not determine investment merit — the Quality and Growth pillars are both Weak, which investors should weigh carefully.
How does TXG compare to its competitors?
10x Genomics occupies a specialized niche in single-cell and spatial biology instrumentation. The companies listed alongside TXG on this page — Hinge Health, Privia Health, and Heartflow — operate in different healthcare technology verticals, making direct operational comparisons limited. The UQS framework scores each company independently across the same five pillars.
What is TXG's market cap bracket?
10x Genomics is classified as a mid-cap company. This places it in a segment of the market that can offer growth potential but may carry more volatility than large- or mega-cap peers in the healthcare sector.
Who founded 10x Genomics?
10x Genomics was founded by Ben Hindson, Serge Saxonov, and Kevin Ness. The company was incorporated in 2012 and was formerly known as 10X Technologies, Inc. before adopting its current name in November 2014.
Is TXG a long-term quality investment?
As a long-term quality indicator, TXG's UQS profile presents a mixed picture. The Neutral Risk and Good Valuation pillars offer some stability, but Weak Quality and Growth ratings suggest the company has not yet demonstrated the durable profitability characteristics typically associated with high long-term quality scores. Pro members can view the full trend analysis.
What is the main competitive advantage of 10x Genomics?
10x Genomics has built proprietary microfluidic technology and a growing installed base of instruments that generate recurring consumables revenue. Its platforms address specialized research workflows in single-cell biology and spatial transcriptomics — areas where switching costs and technical complexity can create some degree of customer retention. The UQS Moat pillar rates this advantage as Neutral.
What sector does TXG belong to?
10x Genomics operates in the Healthcare sector, specifically within life science tools and technology. The company's products serve research applications rather than direct patient care, placing it in the instruments and reagents segment of the broader healthcare market.
Is TXG a growth stock or value stock?
Based on the UQS framework, TXG carries a Weak Growth pillar and a Good Valuation pillar — an unusual combination suggesting the market has already discounted much of the growth uncertainty. It does not fit neatly into either the classic growth or value category at this time.
Unlock Full TXG Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View exact scores for all five UQS pillars
- ✓Access detailed financial metrics and trend data
- ✓Compare TXG against sector peers side by side
- ✓See the complete Quality and Growth breakdown
- ✓Get the full Risk and Valuation deep-dive
- ✓Pro members unlock the complete analyst view
Pro Analysis
TXG — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 22, 2026 | 41.2 | 25.1 | 42.0 | 31.8 | 47.1 | 73.7 | -0.1 |
| May 7, 2026 | 41.3 | 26.0 | 42.0 | 30.3 | 47.1 | 74.9 | -0.1 |
| May 3, 2026 | 41.4 | 26.0 | 42.0 | 30.3 | 47.1 | 75.5 | -0.2 |
| Apr 26, 2026 | 41.6 | 26.0 | 42.0 | 30.3 | 47.1 | 76.6 | +1.2 |
| Apr 19, 2026 | 40.4 | 26.0 | 42.0 | 30.4 | 47.1 | 68.8 | -0.7 |
| Apr 14, 2026 | 41.1 | 26.0 | 42.0 | 30.4 | 47.1 | 73.4 | -0.2 |
| Apr 12, 2026 | 41.3 | 26.0 | 42.0 | 30.4 | 47.1 | 74.3 | -0.2 |
| Apr 10, 2026 | 41.5 | 26.0 | 42.0 | 30.2 | 47.1 | 76.2 | +0.1 |
| Apr 5, 2026 | 41.4 | 26.0 | 42.0 | 29.8 | 47.1 | 76.2 | +0.1 |
| Apr 2, 2026 | 41.3 | 26.0 | 42.0 | 29.8 | 47.1 | 75.1 | — |
TXG — Pillar Breakdown
Quality
— 25.1/100 (25%)10x Genomics, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 31.8/100 (20%)10x Genomics, Inc. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 47.1/100 (15%)10x Genomics, Inc. has some risk factors including moderate leverage or solvency concerns.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 73.7/100 (15%)10x Genomics, Inc. trades at a reasonable valuation with decent earnings yield and FCF multiples.
How many years of FCF the market cap represents.
Moat
— 42/100 (25%)10x Genomics, Inc. possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for TXG.
Score Composition
Financial Data
More Stock Analysis
How is the TXG UQS Score Calculated?
The UQS (Unified Quality Score) for 10x Genomics, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses 10x Genomics, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether 10x Genomics, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.